Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
ORGANIZATION
Experts Eye Macroeconomic Indexing of Drug Costs to Keep Innovation Afloat: INES Proposal
A group of economists has drawn up a proposal on the Japanese drug pricing system, calling for the introduction of “macroeconomic indexing” for pharmaceutical costs to contain fiscal volatility without strangling innovation. The idea is to set a certain cap…
To read the full story
Related Article
- Main Focus of INES Proposal Is Securing Resources to Reward Innovation, Not Macroeconomic Indexing
October 25, 2021
- JPMA Chief Opposes Macroeconomic Indexing, Says Drugs Should Drive Economic Growth
September 22, 2021
- Attention Grows for INES Drug Pricing Proposal; Will It Become Next Card on Reform?
July 12, 2021
ORGANIZATION
- Ex-Govt Advisor Calls for Discussions on Elective Scheme for Biologics
January 29, 2025
- JPMA Exec Urges Rethink of Social Security Funding; Comments on Trump’s Policy
January 24, 2025
- Japan Biosimilar Association Ready to Play Its Roles under Govt Roadmap
January 17, 2025
- JGA to Launch Scheme for Requesting Production Ramp-Up in March: President
January 14, 2025
- Drug Price Cuts for 8 Years Straight Is Big Burden: Trade Group Chief
January 9, 2025
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…